Optimizing Methotrexate Treatment in Rheumatoid Arthritis: The Case for Subcutaneous Methotrexate Prior to Biologics

Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort

(2015) Rüdiger B. Müller et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial

(2014) J L Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration

(2014) Michael H Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial

(2014) P Verschueren et al.   ANNALS OF THE RHEUMATIC DISEASES

Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort

(2014) Elena Nikiphorou et al.   CLINICAL RHEUMATOLOGY

Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects?

(2014) Charles B. Kromann et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study

(2014) DGI Scott et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United States

(2014) Jeffrey R. Curtis et al.   ARTHRITIS CARE & RESEARCH

Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate

(2013) Ray Fitzpatrick et al.   CLINICAL RHEUMATOLOGY

Molecular Basis for Pharmacokinetics and Pharmacodynamics of Methotrexate in Rheumatoid Arthritis Therapy

(2013) Katsuhisa Inoue et al.   Drug Metabolism and Pharmacokinetics

Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs

(2011) VIVIAN P. BYKERK et al.   JOURNAL OF RHEUMATOLOGY

Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study

(2010) M. F. Bakker et al.   ANNALS OF THE RHEUMATIC DISEASES

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy

(2010) C. Deighton et al.   RHEUMATOLOGY

Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative

(2008) K Visser et al.   ANNALS OF THE RHEUMATIC DISEASES